<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03407287</url>
  </required_header>
  <id_info>
    <org_study_id>828397</org_study_id>
    <nct_id>NCT03407287</nct_id>
  </id_info>
  <brief_title>Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid Status</brief_title>
  <acronym>PIVA</acronym>
  <official_title>Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid Status:</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the effects of fluid alternations, hemodynamic changes,&#xD;
      mechanical ventilation, pharmacologic agents, positional changes, and comorbidities on the&#xD;
      Peripheral Intravenous waveform Analysis (PIVA) signal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravascular volume status determination remains elusive. Standard vital sign monitoring,&#xD;
      including heart rate and blood pressure, fails to detect intravascular volume depletion and&#xD;
      volume overload. Likewise, invasive monitoring is fraught with risk including vascular injury&#xD;
      and central line associated infections. As such, a minimally-invasive mechanism to overcome&#xD;
      the barriers of standard monitoring to detect volume status derangement, would be highly&#xD;
      valuable. The goal of the study is to perform a series of observational feasibility studies&#xD;
      in healthy and hospitalized subjects to determine effects of fluid alternations, hemodynamic&#xD;
      changes, mechanical ventilation, pharmacologic agents, positional changes, and comorbidities&#xD;
      on the PIVA signal&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    interim analysis, closed for additional product development&#xD;
  </why_stopped>
  <start_date type="Actual">January 8, 2018</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of PIVA score to standard hemodynamic monitors</measure>
    <time_frame>Baseline to end of monitoring (Approximately 180 minutes)</time_frame>
    <description>Peripheral intravenous waveform analysis score is used to detect intravascular volume status. The scale ranges from 2-40 and is interpreted as a surrogate for pulmonary capillary wedge pressure. The normal scale range is 6-12. A PIVA score of 2 indicates a low intravascular volume and 40 indicates a high intravascular volume.</description>
  </primary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">180</enrollment>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <condition>Distributive Shock</condition>
  <condition>Hypotension and Shock</condition>
  <condition>Decompensated Congestive Heart Failure</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>High Risk Non-cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Cardiac Catheterization</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Distributive shock</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Vasoactive and inotropic agents</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Congestive heart failure</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <description>Patients with atrial fibrillation undergoing elective direct current cardioversion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients undergoing surgery</arm_group_label>
    <description>Patients undergoing surgery requiring positive pressure ventilation and arterial line placement</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral Intravenous Analysis (PIVA)</intervention_name>
    <description>Non-invasive measurement of peripheral venous waveform analysis (PIVA) obtained by connecting a standard transducer (AD Instruments, Colorado Springs, Co) to a universal adaptor or stopcock on a peripheral IV</description>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <arm_group_label>Cardiac Catheterization</arm_group_label>
    <arm_group_label>Congestive heart failure</arm_group_label>
    <arm_group_label>Distributive shock</arm_group_label>
    <arm_group_label>Patients undergoing surgery</arm_group_label>
    <arm_group_label>Vasoactive and inotropic agents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of care invasive vascular monitoring</intervention_name>
    <description>Standard of care invasive monitoring in the intensive care settings with central venous catheters, pulmonary artery catheters, or trans-esophageal echocardiography for determining volume status.</description>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <arm_group_label>Cardiac Catheterization</arm_group_label>
    <arm_group_label>Congestive heart failure</arm_group_label>
    <arm_group_label>Distributive shock</arm_group_label>
    <arm_group_label>Patients undergoing surgery</arm_group_label>
    <arm_group_label>Vasoactive and inotropic agents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard noninvasive vascular monitoring</intervention_name>
    <description>Standard noninvasive vascular monitoring of blood pressure, pulse rate, pulse oximetry and respiratory rate.</description>
    <arm_group_label>Atrial fibrillation</arm_group_label>
    <arm_group_label>Cardiac Catheterization</arm_group_label>
    <arm_group_label>Congestive heart failure</arm_group_label>
    <arm_group_label>Distributive shock</arm_group_label>
    <arm_group_label>Patients undergoing surgery</arm_group_label>
    <arm_group_label>Vasoactive and inotropic agents</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will enroll patients hospitalized at Vanderbilt University Medical Center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Cardiac Catheterization&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Patients undergoing right heart catheterization or left and right heart&#xD;
             catheterizaton; Age &gt;=18&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Cardiac assist devices (intra-aortic balloon pump, ventricular assist devices, and&#xD;
             extra corporeal membrane oxygenation), ongoing ACLS, aortic or mitral valve disease&#xD;
             greater than mild in severity, aortic or mitral valve replacement, active irregular&#xD;
             heart rhythm, patients with restrictive cardiomyopathies (cardiac amyloidosis),&#xD;
             constrictive cardiac disease (constrictive pericarditis or cardiac-tamponade),&#xD;
             congenital heart disease other than foramen ovale, repaired atrial or ventricular&#xD;
             septal defect, female patients who are pregnant or lactating, or patients with known&#xD;
             psychiatric or neurological disease who are unable to consent. Patients who do not&#xD;
             have a functional peripheral IV as part of standard care. Pressors, starches, lipids,&#xD;
             propofol, or D10 or higher running through the PIVA line.&#xD;
&#xD;
        Distributive Shock&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Cardiopulmonary bypass for cardiac procedures within one hour of arriving in the ICU&#xD;
             post-op; Age &gt;=18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac assist devices (intra-aortic balloon pump, ventricular assist devices, and&#xD;
             extracorporeal membrane oxygenation), ongoing ACLS, severe tricuspid regurgitation or&#xD;
             stenosis, patient with restrictive cardiomyopathies (cardiac amyloidosis), patients&#xD;
             receiving pulmonary vasodilators (nitric oxide, sodium nitroprusside, sildenafil),&#xD;
             atrial fibrillation, congenital heart disease, female patients who are pregnant or&#xD;
             lactating, or patients with known psychiatric or neurological disease who are unable&#xD;
             to consent. Patients who do not have a functional peripheral IV as part of standard&#xD;
             care.&#xD;
&#xD;
        Vasoactive and Inotropic Agents&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized patients with central venous access and pulmonary arterial catheter in&#xD;
             place, requiring infusion of vasoactive and/or inotropic agents; Age &gt;=18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac assist devices (intra-aortic balloon pump, ventricular assist devices, and&#xD;
             extracorporeal membrane oxygenation), ongoing ACLS, severe tricuspid regurgitation or&#xD;
             stenosis, patient with restrictive cardiomyopathies (cardiac amyloidosis), patients&#xD;
             receiving pulmonary vasodilators (nitric oxide, sodium nitroprusside, sildenafil),&#xD;
             atrial fibrillation, congenital heart disease, female patients who are pregnant or&#xD;
             lactating, or patients with known psychiatric or neurological disease who are unable&#xD;
             to consent. Patients who do not have a functional peripheral IV as part of standard&#xD;
             care.&#xD;
&#xD;
        Congestive Heart Failure&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting to Vanderbilt University Medical Center with the diagnosis of&#xD;
             congestive heart failure and present with symptoms of fluid overload; Age&gt;=18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac assist devices (intra-aortic balloon pump, ventricular assist devices, and&#xD;
             extra corporeal membrane oxygenation), ongoing ACLS, active irregular heart rhythm,&#xD;
             patient with restrictive cardiomyopathies (cardiac amyloidosis), or constrictive&#xD;
             cardiac disease (constrictive pericarditis or cardiac tamponade), congenital heart&#xD;
             disease other than foramen ovale, repaired atrial or ventricular septal defect, female&#xD;
             patients who are pregnant or lactating, or patients with known psychiatric or&#xD;
             neurological disease who are unable to consent. Patients who do not have a functional&#xD;
             peripheral IV as part of standard care.&#xD;
&#xD;
        Atrial Fibrillation (undergoing elective direct current cardio version)&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with atrial fibrillation undergoing direct current cardioversion; Age &gt;=18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac assist devices (intra-aortic balloon pump, ventricular assist devices, and&#xD;
             extra corporeal membrane oxygenation), ongoing ACLS, patients with restrictive&#xD;
             cardiomyopathies (cardiac amyloidosis) or constrictive cardiac disease (constrictive&#xD;
             pericarditis or cardiac tamponade), congenital heart disease other than foramen ovale,&#xD;
             repaired atrial or ventricular septal defect, female patients who are pregnant or&#xD;
             lactating, or patients with known psychiatric or neurological disease who are unable&#xD;
             to consent. Patients who do not have a functional peripheral IV as part of standard&#xD;
             care.&#xD;
&#xD;
        Patients undergoing Surgery&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients presenting for surgery requiring positive pressure ventilation and arterial&#xD;
             line placement; Age &gt;=18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiac assist devices (intra-aortic balloon pump, ventricular assist devices, and&#xD;
             extra corporeal membrane oxygenation), ongoing ACLS, patients with restrictive&#xD;
             cardiomyopathies (cardiac amyloidosis) or constrictive cardiac disease (constrictive&#xD;
             pericarditis or cardiac tamponade), active irregular cardiac rhythm, congenital heart&#xD;
             disease other than foramen ovale , repaired atrial or ventricular septal defect,&#xD;
             female patients who are pregnant or lactating, patients with known psychiatric or&#xD;
             neurological disease who are unable to consent, or any other medical condition which,&#xD;
             in the opinion of the investigator, would place the patient at undue risk from&#xD;
             participation in the trial. Patients who do not have a functional peripheral IV as&#xD;
             part of standard care.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly L. Kohorst, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>January 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Kelly Kohorst</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

